AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients
Completed
- Conditions
- Infection in ICU
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00543894
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Seretide Diskus (salmeterol/fluticasone) 50/500 μg
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 442
- Registration Number
- NCT00542880
- Locations
- 🇬🇧
Research Site, Hamilton, United Kingdom
Effectiveness of Anti-Psychotic in GPs Setting
Completed
- Conditions
- SchizophreniaBipolar Disorder
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00543088
- Locations
- 🇧🇪
Research Site, Zonnebeke, Belgium
Pan-European Survey on the Under Treatment of Hypercholesterolemia
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2007-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6500
- Registration Number
- NCT00542867
Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID
Phase 3
Completed
- Conditions
- Gastric UlcerDuodenal UlcerRheumatoid ArthritisOsteoarthritisLumbago
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2010-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 343
- Registration Number
- NCT00542789
- Locations
- 🇯🇵
Research Site, Shizuoka, Japan
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1840
- Registration Number
- NCT00542594
Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial
Completed
- Conditions
- Prostate Carcinoma
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2007-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1950
- Registration Number
- NCT00540059
Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients
Phase 1
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00539331
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Phase I Multiple-Ascending Dose (Japan)
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00538174
- Locations
- 🇯🇵
Local Institution, Suita, Osaka, Japan
Liver Safety Under Upfront Arimidex vs Tamoxifen
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 384
- Registration Number
- NCT00537771
- Locations
- 🇨🇳
Research Site, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath